Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Retin Cases Brief Rep ; 12(4): 307-309, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-27997458

RESUMO

PURPOSE: To report a case of acute retinal necrosis in a patient on anti-tumor necrosis factor α immunosuppressive therapy. METHODS: Case report. RESULTS: A 47-year-old man with psoriasis presented with blurred vision and floaters in the left eye 4 days after receiving his fourth dose of adalimumab, a tumor necrosis factor α antagonist. He was diagnosed with acute retinal necrosis and was treated with intravenous acyclovir as well as prophylactic laser barricade. Seven years later, he is 20/20 with no history of a retinal detachment. CONCLUSION: Physicians prescribing tumor necrosis factor α antagonist immunosuppressive therapy should be aware of the potential of developing acute retinal necrosis.


Assuntos
Adalimumab/efeitos adversos , Anti-Inflamatórios/efeitos adversos , Síndrome de Necrose Retiniana Aguda/induzido quimicamente , Humanos , Masculino , Pessoa de Meia-Idade , Fator de Necrose Tumoral alfa/antagonistas & inibidores
2.
Retin Cases Brief Rep ; 10(1): 48-51, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26682796

RESUMO

BACKGROUND/PURPOSE: Postmarket analysis helps identify potentially important side effects not discovered during clinical trials. Ocriplasmin is a recently approved medication administered by intravitreal injection for the treatment of symptomatic vitreomacular adhesion and macular hole. Overall, clinical trials of ocriplasmin have shown a relatively high safety profile. However, recently, a series of case reports have highlighted acute vision loss associated with abnormal findings on spectral domain optical coherence tomography and electroretinography. METHODS/RESULTS: A 70-year-old man developed multiple discrete pockets of macular subretinal fluid 10 weeks after intravitreal ocriplasmin injection, with minimal resolution of fluid over 11 months. Electroretinographic findings demonstrated persistent rod photoreceptor sensitivity loss at 14 months after injection. CONCLUSION: This is the first report of persistent electroretinographic and optical coherence tomographic abnormalities after ocriplasmin injection. Electroretinography abnormalities were noted in a small percentage of patients during ocriplasmin clinical trials and in a recent series of case reports and postmarket survey analysis. The authors propose that cleavage of fibronectin and laminin causes disruption of the interphotoreceptor matrix, leading to the ellipsoid layer attenuation and resultant electroretinographic sensitivity loss and subretinal fluid described on spectral domain optical coherence tomography. Persistent changes over 14 months in this patient indicate that ocriplasmin may have the potential to cause permanent retinal damage.


Assuntos
Fibrinolisina/efeitos adversos , Fibrinolíticos/efeitos adversos , Fragmentos de Peptídeos/efeitos adversos , Doenças Retinianas/induzido quimicamente , Perfurações Retinianas/tratamento farmacológico , Idoso , Humanos , Injeções Intravítreas , Masculino , Células Fotorreceptoras de Vertebrados/fisiologia , Líquido Sub-Retiniano/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...